Research progress of arsenic trioxide in anti-liver cancer mechanism and treatment of hepatocellular carcinoma

doi:10.3760/cma.j.cn371439-20201201-00112

Abstract

Abstract:

Arsenic trioxide (ATO) is involved in a variety of biological processes of hepatocellular carcinoma (HCC) cells, including apoptosis induction, proliferation inhibition, invasion and metastasis inhibition, and tumor stem cell inhibition. ATO has a variety of therapeutic approaches in the treatment of HCC, mainly including single drug therapy, combined local therapy, combined systemic therapy, and so on. Further research on the anti-cancer mechanism and clinical application of ATO is expected to provide new ideas for the treatment of liver cancer.

Key words: Liver neoplasms, Therapeutic uses, Arsenic trioxide

Du Jiahang, Chen Dong, Chen Yaoting. Research progress of arsenic trioxide in anti-liver cancer mechanism and treatment of hepatocellular carcinoma[J]. Journal of International Oncology, 2021, 48(9): 572-.

References 25

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424. DOI: 10.3322/caac.21492. doi: 10.3322/caac.21492
[2]	Jeong SO, Kim EB, Jeong SW, et al. Predictive factors for complete response and recurrence after transarterial chemoembolization in hepatocellular carcinoma[J]. Gut Liver, 2017, 11(3):409-416. DOI: 10.5009/gnl16001. doi: 10.5009/gnl16001 pmid: 28208001
[3]	Jiang F, Li Y, Si L, et al. Interaction of EZH2 and P65 is involved in the arsenic trioxide-induced anti-angiogenesis in human triple-negative breast cancer cells[J]. Cell Biol Toxicol, 2019, 35(4):361-371. DOI: 10.1007/s10565-018-09458-0. doi: 10.1007/s10565-018-09458-0 pmid: 30612216
[4]	Li X, Sun D, Zhao T, et al. Long non-coding RNA ROR confers arsenic trioxide resistance to HepG2 cells by inhibiting p53 expression[J]. Eur J Pharmacol, 2020, 872:172982. DOI: 10.1016/j.ejphar.2020.172982. doi: 10.1016/j.ejphar.2020.172982
[5]	Cai X, Yu L, Chen Z, et al. Arsenic trioxide-induced upregulation of miR-1294 suppresses tumor growth in hepatocellular carcinoma by targeting TEAD1 and PIM1[J]. Cancer Biomark, 2020, 28(2):221-230. DOI: 10.3233/CBM-190490. doi: 10.3233/CBM-190490
[6]	Wang HY, Zhang B, Zhou JN, et al. Arsenic trioxide inhibits liver can-cer stem cells and metastasis by targeting SRF/MCM7 complex[J]. Cell Death Dis, 2019, 10(6):453. DOI: 10.1038/s41419-019-1676-0. doi: 10.1038/s41419-019-1676-0
[7]	Sun Z, Li M, Bai L, et al. Arsenic trioxide inhibits angiogenesis in vitro and in vivo by upregulating FoxO3a[J]. Toxicol Lett, 2019, 315:1-8. DOI: 10.1016/j.toxlet.2019.08.009. doi: 10.1016/j.toxlet.2019.08.009
[8]	Duan X, Li H, Han X, et al. Antitumor properties of arsenic trioxide-loaded CalliSpheres^® microspheres by transarterial chemoembolization in VX2 liver tumor rabbits: suppression of tumor growth, angiogenesis, and metastasis and elongation of survival[J]. Am J Transl Res, 2020, 12(9):5511-5524.
[9]	Wang Y, Jiang F, Jiao K, et al. De-methylation of miR-148a by arsenic trioxide enhances sensitivity to chemotherapy via inhibiting the NF-κB pathway and CSC like properties[J]. Exp Cell Res, 2020, 386(2):111739. DOI: 10.1016/j.yexcr.2019.111739. doi: 10.1016/j.yexcr.2019.111739
[10]	陈耀庭, 胡晓俊, 李丹, 等. 肝细胞癌对三氧化二砷的化疗耐药性机制[J]. 国际肿瘤学杂志, 2016, 43(11):861-864. DOI: 10.3760/cma.j.issn.1673-422X.2016.11.016. doi: 10.3760/cma.j.issn.1673-422X.2016.11.016
[11]	Liu H, Zhang Z, Chi X, et al. Arsenite-loaded nanoparticles inhibit PARP-1 to overcome multidrug resistance in hepatocellular carcinoma cells[J]. Sci Rep, 2016, 6:31009. DOI: 10.1038/srep31009. doi: 10.1038/srep31009
[12]	Huang Y, Zhou B, Luo H, et al. ZnAs@SiO₂ nanoparticles as a potential anti-tumor drug for targeting stemness and epithelial-mesenchymal transition in hepatocellular carcinoma via SHP-1/JAK2/STAT3 signaling[J]. Theranostics, 2019, 9(15):4391-4408. DOI: 10.7150/thno.32462. doi: 10.7150/thno.32462
[13]	Chi X, Zhang R, Zhao T, et al. Targeted arsenite-loaded magnetic multifunctional nanoparticles for treatment of hepatocellular carcinoma[J]. Nanotechnology, 2019, 30(17):175101. DOI: 10.1088/1361-6528/aaff9e. doi: 10.1088/1361-6528/aaff9e
[14]	季峻松, 陈婷, 王辉, 等. 肝动脉化疗栓塞联合灌注三氧化二砷治疗原发性肝癌[J]. 实用医学杂志, 2018, 34(2):251-253. DOI: 10.3969/j.issn.1006-5725.2018.02.023. doi: 10.3969/j.issn.1006-5725.2018.02.023
[15]	Yang H, Zhou S, Shen R, et al. Evaluation on efficacy and safety of arsenic trioxide plus transcatheter arterial chemoembolization versus transcatheter arterial chemoembolization alone for unresectable primary liver cancer[J]. Asian Pac J Cancer Prev, 2017, 18(10):2695-2701. DOI: 10.22034/APJCP.2017.18.10.2695. doi: 10.22034/APJCP.2017.18.10.2695
[16]	Li H, Wu F, Duan M, et al. Drug-eluting bead transarterial chemoembolization (TACE) vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE treatments history: a comparison of efficacy and safety[J]. Medicine (Baltimore), 2019, 98(21):e15314. DOI: 10.1097/MD.0000000000015314. doi: 10.1097/MD.0000000000015314
[17]	Duan XH, Li H, Ren JZ, et al. Hepatic arterial chemoembolization with arsenic trioxide eluting CalliSpheres microspheres versus lipiodol emulsion: pharmacokinetics and intratumoral concentration in a rabbit liver tumor model[J]. Cancer Manag Res, 2019, 11:9979-9988. DOI: 10.2147/CMAR.S199188. doi: 10.2147/CMAR.S199188
[18]	Kong D, Jiang T, Liu J, et al. Chemoembolizing hepatocellular carcinoma with microsphere cored with arsenic trioxide microcrystal[J]. Drug Deliv, 2020, 27(1):1729-1740. DOI: 10.1080/10717544.2020.1856219. doi: 10.1080/10717544.2020.1856219
[19]	Li D, Wei Y, Xu S, et al. A systematic review and meta-analysis of bidirectional effect of arsenic on ERK signaling pathway[J]. Mol Med Rep, 2018, 17(3):4422-4432. DOI: 10.3892/mmr.2018.8383. doi: 10.3892/mmr.2018.8383
[20]	Wang L, Min Z, Wang X, et al. Arsenic trioxide and sorafenib combination therapy for human hepatocellular carcinoma functions via up-regulation of TNF-related apoptosis-inducing ligand[J]. Oncol Lett, 2018, 16(3):3341-3350. DOI: 10.3892/ol.2018.8981. doi: 10.3892/ol.2018.8981
[21]	陈洁盈, 陈耀庭, 林泽宇, 等. 三氧化二砷逆转低浓度索拉非尼对人肝癌细胞促迁移作用及其机制[J]. 中华肝脏外科手术学电子杂志, 2016, 5(2):114-118. DOI: 10.3877/cma.j.issn.2095-3232.2016.02.012. doi: 10.3877/cma.j.issn.2095-3232.2016.02.012
[22]	邬德东, 史继静, 张倩, 等. 索拉非尼联合三氧化二砷治疗晚期原发性肝癌的临床研究[J]. 现代肿瘤医学, 2019, 27(15):2728-2731. DOI: 10.3969/j.issn.1672-4992.2019.15.025. doi: 10.3969/j.issn.1672-4992.2019.15.025
[23]	Kojima-Yuasa A, Huang X, Matsui-Yuasa I. Synergistic anticancer activities of natural substances in human hepatocellular carcinoma[J]. Diseases, 2015, 3(4):260-281. DOI: 10.3390/diseases3040260. doi: 10.3390/diseases3040260 pmid: 28943624
[24]	周珍, 刘少平, 周朗, 等. 黄芩素通过PI3K/AKT通路增强三氧化二砷对肝癌细胞的促凋亡作用[J]. 现代肿瘤医学, 2019, 27(10):1661-1668. DOI: 10.3969/j.issn.1672-4992.2019.10.002. doi: 10.3969/j.issn.1672-4992.2019.10.002
[25]	Shen L, Zhang G, Lou Z, et al. Cryptotanshinone enhances the effect of arsenic trioxide in treating liver cancer cell by inducing apoptosis through downregulating phosphorylated-STAT3 in vitro and in vivo[J]. BMC Complement Altern Med, 2017, 17(1):106. DOI: 10.1186/s12906-016-1548-4. doi: 10.1186/s12906-016-1548-4